Galactosemia Cell Models for Research

Galactosemia is an inherited metabolic disorder caused by defects in galactose metabolism. The most common form, classic galactosemia, results from profound deficiency of galactose-1-phosphate uridylyltransferase (GALT) and occurs in approximately 1 in 30,000 to 60,000 live births worldwide (WHO, 2023). Without newborn screening, affected infants develop life-threatening symptoms including cataracts, hepatomegaly, and Escherichia coli sepsis. With early dietary intervention, acute mortality is reduced, but long-term complications such as cognitive impairment, speech disorders, and premature ovarian insufficiency persist in many patients. The disease imposes a significant lifelong burden on patients and healthcare systems, highlighting the need for better therapeutic strategies.

Galactosemia is an ideal model for studying metabolic pathway dysregulation, gene-environment interactions, and genotype-phenotype correlations. The disease is monogenic, with over 300 mutations identified in the GALT gene, providing a clear link between genetic variation and clinical outcomes. Public datasets, such as the ClinVar database, offer extensive variant information. However, the molecular mechanisms underlying long-term complications remain incompletely understood, and there are no targeted therapies beyond dietary galactose restriction. Gene-edited cell models enable precise dissection of pathogenic mechanisms and facilitate drug screening for novel interventions.

Galactosemia is not a cancer, but it involves metabolic pathways that can be disrupted. The primary pathway is the Leloir pathway, which converts galactose to glucose-1-phosphate. Key steps include:

1. Galactokinase (GALK1) phosphorylates galactose to galactose-1-phosphate.

2. Galactose-1-phosphate uridylyltransferase (GALT) transfers a uridyl group from UDP-glucose to galactose-1-phosphate, producing UDP-galactose and glucose-1-phosphate.

3. UDP-galactose 4-epimerase (GALE) interconverts UDP-galactose and UDP-glucose.

Deficiency in any of these enzymes leads to accumulation of toxic metabolites, such as galactose-1-phosphate and galactitol, which cause cellular damage. In classic galactosemia, GALT deficiency results in the most severe phenotype.

Data from ClinVar and NCBI Gene.

Galactosemia affects multiple cellular processes:

• • Oxidative stress: Accumulation of galactose-1-phosphate induces reactive oxygen species (ROS), leading to mitochondrial dysfunction and apoptosis.
• • Apoptosis: Increased ROS activates the intrinsic apoptotic pathway, involving BAX/BCL-2 and caspases.
• • Inflammatory response: Galactitol accumulation triggers endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), activating NF-κB and pro-inflammatory cytokines.
• • Epigenetic modifications: Altered glycosylation patterns affect gene expression and cellular signaling.

Key nodes in these networks include NRF2, p53, and AKT.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, recapitulating tissue architecture and metabolic functions.

• • GALT knockout mice: Generated by homologous recombination; exhibit elevated galactose-1-phosphate and galactitol, but do not fully recapitulate human symptoms.
• • GALK1 knockout mice: Develop cataracts when fed galactose.
• • GALE mutant mice: Show growth retardation and neurological deficits.
• • Patient-derived xenograft (PDX) models are not applicable for metabolic diseases, but humanized mouse models expressing mutant GALT are being developed.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For galactosemia, researchers can generate:

• • GALT knockout cell lines: Complete loss of enzyme activity, mimicking classic galactosemia.
• • GALT point-mutation knock-in lines: Introduction of specific patient mutations (e.g., p.Q188R, p.K285N) to study genotype-phenotype correlations.
• • GALK1 or GALE knockout lines: To model other forms of galactosemia.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems for mechanistic studies and drug screening.

Gene-edited cell lines are essential for validating the functional impact of GALT mutations. For example, introducing a specific missense mutation into a wild-type cell line allows researchers to assess its effect on enzyme activity and cellular phenotype. Conversely, correcting a mutation in patient-derived cells (using CRISPR) can rescue the phenotype, confirming causality. These models also enable genome-wide CRISPR screens to identify modifier genes that influence disease severity.

Isogenic pairs (wild-type vs. GALT knockout) are used to screen for compounds that reduce toxic metabolite accumulation or rescue cellular function. High-throughput screening can identify small molecules that enhance residual enzyme activity or activate alternative pathways. Additionally, gene-edited cells can be used to test the efficacy of pharmacological chaperones or gene therapy vectors.

CRISPR-engineered cells are valuable for identifying biomarkers of disease progression and treatment response. For example, transcriptomic and proteomic profiling of GALT knockout cells can reveal novel biomarkers that are measurable in patient blood. Synthetic lethality screens can identify genes whose knockdown is selectively lethal in GALT-deficient cells, providing potential therapeutic targets.